Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte
As filed · General Updates
What happened
FactSpecialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma. Services Private Limited and Onesource Specialty Pharma Limited and their respective shareholders.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
DelayedEBITDA at ₹173 million, down 88% YoY, due to lower revenue in the quarter and largely fixed cost base
EBITDA has also come in at INR1,233 million, which has been up significantly, 39% year-on-year, as well as sequentially 34% versus last quarter, and which has been in line when we have said last time that we will be showing a sequential quarter-on-quarter growth.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- you will see, this addition will be a significant contributor to our FY28 numbers (management committed by FY28)
- $400 million in organic revenue with 40% EBITDA margin (management committed by FY28)
Evidence
- Onesource Specialty Pharma Limited has informed the Exchange about General Update on Composite Scheme of Amalgamation (Merger by Absorption) amongst SteriscienceSpecialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides PharmaServices Private Limited and Onesource Specialty Pharma Limited and their respective shareholders -(opens the original filing in a new tab)
- Earlier statement · Q3 FY26
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- MERGER base 74; +4 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%